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Abstract 27 
 28 
N6-methyladenosine (m6A) is an abundant internal RNA modification in both coding1 and 29 
non-coding RNAs2,3, catalysed by the METTL3/METTL14 methyltransferase complex4. 30 
Here we define a novel pathway specific for METTL3, implicated in the maintenance of the 31 
leukaemic state. We identify METTL3 as an essential gene for growth of acute myeloid 32 
leukaemia (AML) cells in two distinct genetic screens. Down-regulation of METTL3 results 33 
in cell cycle arrest, differentiation of leukaemic cells and failure to establish leukaemia in 34 
immunodeficient mice. We show that METTL3, independently of METTL14, associates 35 
with chromatin and localizes to transcriptional start site (TSS) of active genes. The vast 36 
majority of these genes have the CAATT-box binding protein CEBPZ present at the TSS5, 37 
which is required for recruitment of METTL3 to chromatin. Promoter bound METTL3 38 
induces m6A modification within the coding region of the associated mRNA transcript, and 39 
enhances its translation by relieving ribosome stalling. We show that genes regulated by 40 
METTL3 in this way are necessary for AML. Together, these data define METTL3 as a 41 
regulator of a novel chromatin-based pathway necessary for maintenance of the leukaemic 42 
state and identify this enzyme as a novel therapeutic target for AML.  43 
  44 
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Main text 45 
 46 
 47 
To identify RNA modifying enzymes necessary for survival and proliferation of AML cells, 48 
we performed two independent CRISPR screens. Firstly, we performed an ex vivo genome 49 
wide CRISPR dropout screen (Screen 1) using Cas9-expressing mouse primary 50 
leukaemia cells driven by an MLL-AF9 fusion gene and a FLT3 internal tandem 51 
duplication6 (Fig. 1a). This identified 1550 dropout targets with a false discovery rate (FDR) 52 
of 0.25 (Supplementary Table 1), including 75 genes encoding possible RNA modifying 53 
enzymes whose expression is necessary for growth of primary leukaemia cells (see 54 
Methods; Supplementary Table 2). 55 
 56 
Cas9-induced indel mutations induce stronger negative selection in dropout screens when 57 
critical functional domains are targeted7. Therefore, we constructed a custom domain-58 
focused gRNA library including the 75 RNA modifying enzymes identified above (Screen 59 
2). This identified 46 high-confidence potential RNA modifying enzymes whose catalytic 60 
activity is required for leukaemia cell growth (Fig. 1b and Supplementary Table 2). Despite 61 
showing high overall correlation, comparison between the two screens highlights targets 62 
whose catalytic activity is specifically required for leukaemia cell growth (Extended Data 63 
Fig. 1a). 64 
 65 
Two Mettl family members, Mettl3 and Mettl16, scored very highly, whilst Mettl14 and 66 
Mettl1 showed significant but lower negative selection. METTL3 and METTL14 form a 67 
complex that catalyses RNA adenosine N6-methylation (m6A)4. METTL16 is also an m6A 68 
methyltransferase8. This modification is present in mRNAs1, pre-miRNA2 and long non-69 
coding RNAs3, and it affects mRNA stability9,10 and translation11. Interestingly, an m6A 70 
demethylase, FTO, which is required for human leukaemia cell growth12 was not identified 71 
 3
in our Screen 1, which may be explained by the heterogeneous genetic background of 72 
human AML cell lines. 73 
 74 
We validated our results using growth competition assays with individual gRNAs targeting 75 
the catalytic domain of Mettl3 and Mettl16 (like in Screen 2) in mouse AML cells  76 
(Extended Data Fig. 1b). Furthermore, negative selection of gRNAs targeting either early 77 
exons (like Screen 1) or the catalytic domain of METTL3 was validated in different mouse 78 
primary leukaemia cell lines (Extended Data Fig. 1c). Finally, disruption of Mettl3's catalytic 79 
domain strongly suppresses primary murine AML cell colony formation (Fig. 1c and 80 
Extended Data Fig. 1d). In contrast, targeting Mettl3 in non-transformed NIH3T3 and 81 
primary haematopoietic cells had no significant effect (Extended Data Fig. 1e and 1f). Our 82 
findings indicate that these genes are specifically essential for AML cell survival and not 83 
for general cellular viability. 84 
 85 
We next targeted METTLs 1, 3, 14 and 16 in ten different human AML cell lines and 10 cell 86 
lines from heterogeneous cancer types. All four METTLs show negative selection in all 87 
AML cell lines tested (Extended Data Fig. 1g), but display varying degrees of negative 88 
selection in non-AML tumours (Extended Data Fig. 2a). These differences are not due to 89 
variable editing levels across cell lines (Extended Data Fig. 2b). 90 
 91 
METTL3 disruption reverses the myeloid differentiation block characteristic of AML, in both 92 
mouse and human AML cells (Fig.  1d and Extended Data Fig. 2c and d).  Increased 93 
expression of CD11b, a granulocytic differentiation marker13, occurred in all METTL3-94 
domain-knockout (KO) cells analysed, consistent with METTL3 loss promoting AML cell 95 
differentiation. Strikingly, targeting METTL3's methyltransferase domain markedly impairs 96 
human leukaemic cell engraftment into immunocompromised mice (Fig.  1e and Extended 97 
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Data Fig. 2e), with animals surviving significantly longer than controls (Fig. 1f). An 98 
independent genetic approach, using human MOLM13 cells harbouring inducible METTL3-99 
specific shRNAs, was used to validate our findings. These cells showed near-complete 100 
loss of METTL3 mRNA and protein upon tetracycline induction of shRNAs (Extended Data 101 
Fig. 3a and b) and markedly reduced proliferation (Fig. 1g). Similar results were obtained 102 
using human AML cell line THP1 (Extended Data Fig. 3c). Importantly, ectopic expression 103 
of METTL3 (Extended Data Fig. 3d) fully rescued the proliferation defect, whilst a 104 
catalytically inactive mutant failed to do so (Fig. 1h), confirming that loss of growth was 105 
due to lack of METTL3's catalytic activity. 106 
 107 
RNA-seq of METTL3 knock-down (KD) cells showed altered expression of transcripts, 108 
both upregulated (n=167) and downregulated (n=180; Extended Data Fig. 3e and 109 
Supplementary Table 3). Gene ontology analysis of differentially expressed genes 110 
revealed down-regulation of cell cycle and up-regulation of haematopoietic cell 111 
differentiation pathways, mirroring our findings obtained using CRISPR-Cas9 and flow 112 
cytometry analyses (Extended Data Fig. 3f and Supplementary Table 4). These data 113 
demonstrate that METTL3 is required for leukaemic cell growth and that its inactivation 114 
induces differentiation of MLL-AF9-driven AML cells. 115 
 116 
Next we interrogated METTL3 expression levels across different cancer samples from the 117 
TCGA dataset14. Interestingly, highest expression of METTL3 (but not METTL14) was 118 
identified in AML cells, diffuse large B-cell lymphoma and prostate adenocarcinoma cells 119 
(Extended Data Fig. 4a). Strikingly, these three cancer types correspond to the cell lines 120 
sensitive to METTL3 targeting (Extended Data Fig. 1g and 2a). Furthermore, METTL3 121 
over-expression in human AML cell lines increases their proliferation (Extended Data Fig. 122 
4b). These observations are consistent with METTL3 playing an oncogenic role in AML. 123 
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 124 
We previously described that cytoplasmic signalling enzymes can directly regulate genes 125 
by binding chromatin15. We therefore tested whether METTL3 binds chromatin. We 126 
detected both METTL3 and its partner METTL14 associated with chromatin fractions from 127 
MOLM13 cells (Extended Data Fig. 4c). To identify genomic loci bound by METTL3 and/or 128 
METTL14, we performed chromatin immunoprecipitation (ChIP) using antibodies against 129 
METTL3, METTL14 and H3K4me3. This identified 126 METTL3 and 119 METTL14 130 
genomic peaks (Fig. 2a, Extended Data Fig. 4d and Supplementary Table 5). Both 131 
METTL3 and METTL14 localized mainly to TSSs of coding genes characterized by 132 
bimodal H3K4me3 peaks (e.g. Fig. 2a, b and Extended Data Fig. 4e and f). Surprisingly, 133 
the two METTLs did not bind the same TSSs (Extended Data Fig. 4g and 5a), suggesting 134 
they have distinct roles on chromatin. Here, we focus on METTL3 and its functions. We 135 
validated several METTL3 peaks using two different METTL3-specific antibodies by ChIP-136 
qPCR (Extended Data Fig. 5b and c) and confirmed reduction of METTL3 ChIP signal at 137 
specific promoters upon METTL3 KD (Fig. 2c and Extended Data Fig. 5d).  138 
 139 
We interrogated sequences under METTL3 peaks for enriched motifs and identified the 140 
CCAAT-box as the top hit (Extended Data Fig. 6a). This motif binds the NFY complex16, 141 
which associates with H3R2me2s and WDR5 on active promoters17. Another significantly 142 
enriched METTL3 peak motif is that for transcription factor KLF9. Using existing ChIP-seq 143 
datasets5 we observed high correlation between METTL3 binding sites and all of these 144 
factors. METTL14 peaks showed no correlation with the same factors except WDR5 145 
(Extended Data Fig. 6b). Co-occupancy by all of these factors on 447 promoters overlaps 146 
with METTL3 binding (Extended Data Fig. 6c and d), but their combined predictive power 147 
for defining METTL3 bound sites is limited. 148 
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We then selected genes most tightly co-expressed with METTL3 (top 2.5 percentile) in 149 
normal and cancer cell lines18. 11 AML Encode ChIP-seq datasets are available for these 150 
co-expressed factors5, including WDR5 (Extended Data Fig. 7a). Amongst them, CEBPZ 151 
shows high co-expression (Extended Data Fig. 7b) and ChIP co-localisation with METTL3 152 
(Fig. 2d, e and Extended Data Fig. 7c and d), but not with METTL14 (Extended Data Fig. 153 
7e). Interestingly, CEBPZ is a CCAAT-box binding factor and is amongst the top dropouts 154 
in the genomic CRISPR-Cas9 screen (Supplementary Table 1 and Extended Data Fig. 7f). 155 
CEBPZ KD in MOLM13 cells (Extended Data Fig. 7g) impairs cell proliferation (Extended 156 
Data Fig. 7h), as shown for METTL3. 157 
 158 
To test whether CEBPZ is involved in recruiting METTL3 to TSSs, we performed METTL3 159 
ChIP-qPCR experiments upon CEBPZ KD. Figure 2f and Extended Data Figure 7i show 160 
reduction of chromatin-bound METTL3 at several promoters in CEBPZ KD cells. This 161 
shows for the first time that METTL3 and METTL14 are recruited to highly specific 162 
chromatin sites, with METTL3 localizing to TSSs with a well-defined signature of 163 
transcription factors and histone modifications. This suggested METTL3 regulates gene 164 
expression of mRNAs derived from its chromatin target genes. 165 
 166 
Transcriptional profiling of METTL3-depleted cells showed that levels of mRNAs 167 
transcribed from METTL3-bound genes were not affected (Extended Data Fig. 7j and 168 
Supplementary Table 3; OR=0.75; p=1). Given that METTL3's catalytic activity is essential 169 
for AML cell growth (Fig. 1h), we investigated post-transcriptional events that could be 170 
regulated by METTL3-mediated RNA methylation.  171 
 172 
To identify RNAs methylated by METTL3 in AML, we performed RNA-immunoprecipitation 173 
linked to high throughput sequencing using an m6A-specific antibody (m6A-IP). We used 174 
 7
RNA isolated from MOLM13 cells (CTRL) and from METTL3-depleted cells. This identified 175 
4085 METTL3-dependent m6A peaks on poly-A+ enriched RNA (Supplementary Table 6, 176 
Extended Data Fig. 8a and b). As expected, we observed widespread reduction of m6A 177 
upon METTL3 KD (Extended Data Fig. 8c). 178 
 179 
We then considered the distribution of m6A in transcripts derived specifically from 180 
METTL3-bound genes, 72.4% of which contained m6A peaks, compared to 38.4% of all 181 
transcripts (OR=4.2; p=5e-04). The m6A levels on mRNA encoding transcription factor 182 
SP1 are shown as an example (Fig. 3a). The majority of METTL3-dependent m6A occurs 183 
within the coding region of transcripts of METTL3-bound genes, in contrast to its 184 
distribution in the general transcriptome, where it is enriched within mRNA 3’UTRs (Fig. 3b 185 
and Extended Data Fig. 8d). 186 
 187 
To investigate whether promoter-bound METTL3 is required for m6A modification of 188 
associated transcripts, we measured m6A modification in these mRNAs following CEBPZ 189 
KD, since this leads to loss of METTL3 at TSSs (Fig. 2f). This demonstrated reduced m6A 190 
in relevant mRNAs (Fig. 3c and Extended Data Fig. 8e). In contrast, no changes were 191 
observed in control mRNAs such as GAPDH. As expected, CEBPZ KD did not affect 192 
mRNA levels of METTL3 chromatin targets or levels of METTL3 itself (Extended Data Fig. 193 
8f). 194 
 195 
Analysis of the whole coding sequences of these transcripts revealed enrichment of a 196 
[GAG]n motif (Fig. 3d). This motif, whilst common throughout coding transcripts, is 197 
significantly over-represented amongst transcripts derived from METTL3-bound genes 198 
(Extended Data Fig. 8g). Interestingly, the motif's reading frame (+2) is preserved 199 
throughout transcripts derived from METTL3-bound genes (Fig. 3e). Although the 200 
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significance of this motif remains unclear, its presence suggests these GAG rich 201 
transcripts require m6A modification for translational efficiency (TE). We therefore 202 
performed ribosome footprinting (RFP) of CTRL and METTL3 KD MOLM13 cells, to 203 
evaluate their translational output (Extended Data Fig. 9a, b and c). Intriguingly, while 204 
mRNAs marked by m6A generally tended to have an increased TE upon METTL3 KD (as 205 
seen by others19), the transcripts derived from genes harbouring METTL3 on their 206 
promoter were translated less efficiently (Fig. 3f and Supplementary Table 7). We 207 
therefore mapped ribosomal pausing sites on mRNAs produced from METTL3-bound 208 
genes. P-site codon occupancy in these transcripts indicated that four codons, GAG, GAT, 209 
GAC, GAA (GAN codons), are more occupied by ribosomes in METTL3 KD cells 210 
compared to CTRL cells (Fig. 3g and Extended Data Fig. 9d). The same was not observed 211 
as a general feature throughout the transcriptome (Extended Data Fig. 9e and f) and is not 212 
due to general over-representation of GAN codons throughout transcripts (Extended Data 213 
Fig. 9g).  214 
 215 
To better characterise how METTL3 regulates translation, we focused on two genes 216 
expressing the transcription factors SP1 and SP2, which have promoters occupied by 217 
METTL3. The levels of SP1 and SP2 proteins are reduced upon METTL3 depletion 218 
(Figure 4a), but their mRNA levels are unaffected (Extended Data Fig. 10a). Indeed, a 219 
similar reduction in SP1 protein levels is observed upon CEBPZ KD (Extended Data Fig. 220 
10b). We next asked how METTL3 KD affects SP1 and SP2 mRNA association with 221 
polysomes (Extended Data Fig. 10c).  Upon METTL3 depletion, there is a specific shift of 222 
SP1 and SP2 transcripts towards lower molecular weight polysomes (Figure 4b), indicating 223 
less efficient translation, whilst there are no differences for control mRNAs (Extended Data 224 
Fig. 10d).  225 
 226 
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The above results demonstrate that METTL3 affects translation of the mRNAs whose 227 
promoters it occupies. We next aimed to prove that recruitment of METTL3 to promoters is 228 
sufficient for this effect. For this, we used a reporter system (Fig. 4c) consisting of a 229 
plasmid harbouring GAL4 binding sites upstream of a constitutive promoter that expresses 230 
an SP2 (m6A peak)-luciferase mRNA fusion. We expressed METTL3 wild type catalytic 231 
domain, or an inactive point mutant20, in-frame with GAL4 DNA-binding domain.  232 
Consistently, only recruitment of wild type METTL3-GAL4 enhanced luciferase activity (Fig. 233 
4d and Extended Data Fig. 10e), without affecting luciferase mRNA levels (Extended Data 234 
Fig. 10f). These data corroborate the model that promoter-bound METTL3 augments 235 
translation of its target genes. 236 
 237 
Consistent with SP1 and SP2 protein depletion in METTL3 KD cells, genes directly bound 238 
and regulated by these factors5 were also generally down-regulated in METTL3 depleted 239 
MOLM13 cells (Extended Data Fig. 10g).  Amongst these is the c-MYC oncogene, whose 240 
promoter is bound by both SP1 and SP2 (Extended Data Fig. 10h and Supplementary 241 
Table 3). We then tested whether loss of SP1 could explain the proliferation defect caused 242 
by METTL3 depletion. Figure 4e shows that ectopic over-expression of SP1 in METTL3 243 
KD cells (Extended Data Fig. 10i) rescues cell growth.  Strikingly, CRISPR targeting of 244 
SP1 is lethal in cell lines, and only in cell lines, that show sensitivity to METTL3 245 
inactivation (Fig. 4f). These observations suggest that the sensitivity of leukaemic cells to 246 
the loss of METTL3 is dictated by the requirement of SP1 for cell growth.  247 
 248 
Here we define a set of RNA modifying enzymes necessary for AML leukaemia and we 249 
identify a new leukaemic pathway for the METTL3 RNA methyltransferase.  In this 250 
pathway, METTL3 is stably recruited by CEBPZ to promoters of a specific set of active 251 
genes, resulting in m6A methylation of the respective mRNAs and increased translation. 252 
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One important target is SP1, an oncogene in several cancers21, which regulates c-MYC 253 
expression22. Consistent with these findings, it was recently reported that METTL3 can 254 
methylate its targets co-transcriptionally23.  255 
 256 
METTL3 affects mRNA translation in numerous ways, including by promoting RNA loading 257 
onto ribosomes24 and recruiting specific m6A reader proteins (e.g. YTHFD1)25. The  258 
findings presented here provide significant insight into the mechanisms through which 259 
METTL3 promotes post-transcriptional regulation of gene expression. They identify a new 260 
paradigm for selecting RNAs to be modified, namely the stable recruitment of the RNA 261 
modifying enzyme to specific genomic loci. They also demonstrate a new mechanism by 262 
which m6A can affect translation, namely relief of ribosome stalling at GAN codons of 263 
specific transcripts. 264 
 265 
The new pathway described here is critical for AML leukaemia since three of its 266 
components are required for AML cell growth: (i) the m6A RNA methyltransferases 267 
METTL3, (ii) the transcription factor CEBPZ, which targets this enzyme to promoters and 268 
(iii) SP1, whose translation is dependent upon the m6A modification by METTL3. Together, 269 
these observations define METTL3 enzymatic activity as a new candidate target for the 270 
treatment of AML. 271 
 272 
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Figure 1 363 
METTL3 is essential for AML cells both in vivo and in vitro. 364 
a) Dropout p-values of the genome-wide screen in MLL-AF9/FLT-ITD cells are displayed. Discontinuous blue 365 
line shows the 25%FDR threshold. RNA enzymes are shown as red dots. b) CRISPR score for the 75 RNA 366 
enzymes (black circles) or the METTL family members (red/blue) as controls in AML-AF9 RN2C cells. c) 367 
Colony forming assay of MLL-AF9/FLT3-ITD-Cas9 cells targeted for Mettl3 (catalytic domain-specific) or 368 
CTRL showing decreased replating ability. Mean+S.D. of three independent replicates is shown; CFU: 369 
colony forming units. (***p< 0.001; t-test). d) CD11b expression in METTL3 (catalytic domain-specific) 370 
targeted cells (MLL-AF9/FLT-ITD mouse cells and MOLM13 human cells) was measured by flow cytometry 8 371 
days (mouse) and 6 days (human) after infection. e) Bioluminescence imaging of mice transplanted with 372 
luciferase-expressing MOLM13 cells transduced with the indicated gRNAs. f) Kaplan-Meier plot showing the 373 
survival time of mice from Fig. 1e. A log rank test was performed. g) Proliferation assay of METTL3 KD or 374 
CTRL cells measured between day 4 and day 8 after tetracycline induction. Mean+S.D. of three independent 375 
replicates is shown. h) Proliferation assay of MPN1c/Flt3ltd/+/Rosa26Cas9/+ mouse Leukaemia cells transduced 376 
with gRNA targeting the catalytic domain of METTL3 and plasmids expressing  wild type METTL3 or a 377 
catalytically inactive mutant. Mean+S.D. of three independent replicates is shown. (**p< 0.01; t-test). 378 
 379 
 380 
 381 
Figure 2 382 
METTL3 localises on specific TSSs on chromatin. 383 
a) Genomic visualisation of METTL3 and H3K4me3 ChIP-seq dataset at the SP2 locus. b) Distribution of 384 
METTL3 ChIP-seq reads centred on TSSs (upper panel) and histogram of ChIP-seq reads distribution 385 
relative to TSSs (lower panel). c) METTL3 ChIP-seq validation by ChIP-qPCR on the SP2 TSS in CTRL or 386 
METTL3 KD MOLM13 cells, showing a specific reduction of METTL3 binding in KD cells. Mean+S.D.  of 387 
three technical replicates is shown. The experiment was performed independently three times. d) Venn 388 
diagram showing the overlap between CEBPZ and METTL3 ChIP-seq peaks. e) Distribution and heatmaps 389 
of normalised ChIP-seq reads for CEBPZ centred on METTL3 peaks. f) ChIP-qPCR of METTL3 binding on 390 
target TSSs in and MOLM13 cells, expressing a control shRNA or two independent shRNAs against CEBPZ, 391 
showing a specific reduction of METTL3 binding in CEBPZ KD cells. Mean+S.D.  of three technical replicates 392 
is shown. The experiment was performed independently three times.   393 
 394 
 395 
 396 
Figure 3 397 
Transcripts derived from METTL3-bound promoters harbour m6A whithin their CDS. 398 
a) Genomic visualisation of the m6A-IP normalised signal in METTL3 KD or CTRL MOLM13 cells on the SP1 399 
transcript (upper tracks), along with the genomic visualisation of the METTL3 ChIP-seq. b) Pie charts of the 400 
distribution of METTL3-dependent m6A peaks within the whole transcriptome or METTL3 chromatin targets 401 
mRNAs. c) m6A-IP followed by qPCR for M6A peaks of SP1, SP2 and HNRNPL or GAPDH as a control. 402 
The plot show the m6A-IP signal over total input in MOLM 13 cells expressing a control shRNA or shRNAs 403 
targeting CEBPZ. Mean+S.D. of three technical replicates are shown; the experiment has been performed 404 
independently twice. d) Motif enriched in mRNAs from METTL3-bound TSSs.  e) Reading frame distribution 405 
of the [GAG]n motif on the transcripts produced at METTL3-bound TSSs. Significance was obtained by 406 
multinomial test. f) Box plot showing the difference in translational efficiency (TE) between METTL3 KD and 407 
CTRL cells. The distributions of log2FC(TE) for all coding genes, mRNAs harbouring METTL3-dependent 408 
m6A and mRNAs originated from METTL3-bound or METTL14-bound TSSs are shown (*p<0.05; Wilcoxon 409 
test). g) Frequency of P-site occupancy of GAN codons in METTL3 KD or CTRL MOLM13 cells (*p<0.05; t-410 
test). 411 
 412 
 413 
Figure 4 414 
Negative effect of METTL3 depletion on the translation efficiency of genes necessary for AML growth. 415 
a) Western blot showing METTL3, SP1, SP2 and ACTIN protein levels in MOLM13 cells infected with 416 
METTL3-specific or CTRL TET-inducible shRNAs 8 days after doxycycline treatment. Two independent 417 
biological replicates are shown. For gel source data see Supplementary Information. b) SP1 and SP2 418 
mRNAs in each ribosome fraction were quantified through qPCR and plotted as a percentage of the total. 419 
Data are from two independent polysome-profiling experiments. Mean ±SEM are shown..c) Schematic 420 
representation of the engineered reporter system. d) Firefly luciferase activity from UAS or scrambled (SCR) 421 
sequence carrying plasmid in presence of GAL4 either alone or fused with METTL3 wild type (CD) or 422 
inactive (CD DW/AA) catalytic domain (*p<0.05; t-test). The mean +S.D. of three independent transfections 423 
is shown, for two different cell lines (HT-29 and FADU) e) Proliferation assay of MOLM13 cells infected with 424 
METTL3-specific or CTRL TET-inducible shRNAs and with an SP1 expression vector between day 3 and 425 
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day 6 after doxycycline treatment. Mean+S.D. of three independent replicates is shown. f) Competitive co-426 
culture assay showing negative selection of BFP+ human tumour cell lines upon targeting of METTL3 or SP1 427 
by CRISPR-Cas9. Results were normalized to day 4 for each gRNA. Mean+S.D. of two independent 428 
infections is shown. 429 
 
Materials and Methods (Online only) 
 
Cell culture 
MOLM13, THP-1, MV4-11, NOMO-1, HL-60, EOL-1, KG-1, RN2c, HEL, JURKAT, LOUCY, 
K562 cells were cultured in RPMI1640 (Invitrogen) supplemented with 10% FBS and 1% 
penicillin/streptomycin/glutamine. OCI-AML2 and OCI-AML3 cells were cultured in Alpha-
MEM supplemented with 20% FBS and 1% penicillin/streptomycin/glutamine. 293T, 
mouse immortalized fibroblasts NIH-3T3, SU-DHL-4, HT1080, SBC-3, DETROIT-562, 
FADU, SH-SY5Y and HT-29 cells were cultured in DMEM (Invitrogen), supplemented with 
10% FBS and 1% penicillin/streptomycin/glutamine. 293T, FADU and HT-29 cells were 
transfected using the Lipofectamine 2000 reagent (Invitrogen) according to the 
manufacturer instructions. All human cancer cell lines were obtained from the Sanger 
Institute Cancer Cell Collection and tested to be negative for mycoplasma contamination. 
Human cell lines employed are not listed in the cross-contaminated or misidentified cell 
lines database curated by the International Cell Line Authentication Committee (ICLAC). 
 
Isolation of haematopoietic progenitors 
Flt3ITD/+ mice26 were kindly provided by Gary Gilliland and crossed with Rosa26Cas9/+ mice6. 
Freshly isolated bone marrow from 6- to 10-week-old female Rosa26Cas9/+, Flt3ITD/+; 
Rosa26Cas9/+ or moribund Npm1flox−cA/+; Flt3ITD/+ mice was used. Bone marrow cells were 
exposed to erythrocyte lysis (BD PharmLyse, BD Bioscience), followed by magnetic bead 
selection of Lin- cells using the Lineage Cell Depletion Kit (Miltenyi Biotec) according to the 
manufacturer’s instructions. Lin- cells were cultured in X-VIVO 20 (Lonza) supplemented 
with 5% BIT serum substitute (Stem Cell Technologies), 10ng ml-1 IL3 (Peprotech), 10ng 
ml-1 IL6 (Peprotech) and 50ng ml-1 of SCF (Peprotech). Retrovirus constructs pMSCV-
MLL-AF9-IRES-YFP and pMSCV-MLL-ENL-IRES-Neo were used with package plasmid 
psi-Eco to produce retrovirus. 293T cells (Life Technologies) were cultured and prepared 
for transduction in 10cm plates as described above. For virus production, 5 μg of the 
above plasmids and 5 μg psi-Eco packaging vector were transfected drop wise into the 
293T cells using 47.5 μl TransIT LT1 (Mirus) and 600 μl Opti-MEM (Invitrogen). 
Transduction of primary mouse cells was performed in 6-well plates as mentioned above. 
After transduction, cells were sorted for YFP (for MLL-AF9) or selected with neomycin (for 
MLL-ENL). 
 
Generation of genome-wide mutant libraries and screening  
Ex-vivo CRISPR screens were performed using the previously reported WT Sanger 
genome-wide CRISPR library6, which employs 5 gRNA for each of the 18424 targeted 
genes. 3.0 × 107
 
cells were infected with a pre-determined volume of the genome-wide 
gRNA lentiviral supernatant that gave rise to 30% transduction efficiency measured by 
BFP expression. Two independent infections were conducted for the murine primary AML 
cells. Two days after transduction, the cells were selected with puromycin at 1.5 μg ml-1. 
Genomic DNA extraction and Illumina sequencing of gRNAs were conducted as described 
previously6. For the primary murine AML screen, 19-bp single-end sequencing was 
performed with the custom sequencing primer 5’-
TCTTCCGATCTCTTGTGGAAAGGACGAAACACCG-3’. The number of reads for each 
guide was counted with an in-house script. Enrichment and depletion of guides and genes 
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were analyzed using MAGeCK statistical package27 by comparing read counts from each 
cell line with counts from matching plasmid as the initial population. 
The 296 RNA enzyme list which has been interrogated for dropouts was compiled as 
follows: 171 SAM-binding proteins without known histone methyltransferase activity; 65 
ATP-dependent helicases with reported RNA interaction in at least 3 out of 4 CLIP 
datasets28–31; 12 Pseudouridylases; 48 annotated RNA enzymes not included in the 
previous lists (Supplementary Table 2) 
 
Lentiviral vectors production and infection. 
For virus production 293T cells were transfected with the appropriate Lentiviral vector 
(PLKO.1 for shRNA, LRG and LentiCRISPR-v2 for CRISPR-Cas9) together with the 
packaging plasmids PAX2 and VSVg at a 1:1.5:0.5 ratio. Supernatant was harvested 48 
and 72 hours after transfection. 
1x106
 
cells and viral supernatant were mixed in 2 ml of culture medium supplemented with 
8 μg ml-1 (human) or 4 μg ml-1 (mouse) polybrene (Millipore), followed by spinfection (60 
min, 900 g, 32 °C) and further incubated overnight at 37 °C. The medium was refreshed on 
the following day and the transduced cells were cultured further. 
 
Pooled domain-focused CRISPR gRNA construction 
For the RNA enzyme domain-focused CRISPR screen, 5 gRNAs were designed to target 
the catalytic domain of each protein based on the NCBI database annotation. gRNAs were 
synthesized in a pooled format on an array platform (Twist Bioscience) and PCR-cloned 
into a lentiviral gRNA expression vector (LRG, Addgene: #65656). To check the 
representation and identity of individual gRNAs within the lentiviral pool, a deep-sequence 
analysis was performed. This confirmed that 100% of the designed gRNAs were cloned in 
the LRG vector and the abundance of >95% of the gRNA constructs was within 5-folds of 
the mean. 
 
Pooled gRNA screening, Miseq library construction, and data analysis 
Virus containing the domain-focused gRNA library against RNA modifying enzymes was 
generated as described above. A serial dilution of this virus in correlation with the GFP+ 
cell population was used to estimate the viral titer multiplicity of infection (MOI). In the 
initial infected cell population, the total number of RN2c cells corresponded to an 
approximately one thousand-fold representation of each gRNA. To ensure that a single 
gRNA was transduced per cell, the viral volume for infection corresponded to an MOI of 
0.4~0.5. At 2 days post-infection, a portion of the RN2c cells was harvested and used as a 
reference time point. At the end point of the negative selection experiment, a portion of the 
RN2c cells was harvested again and saved for gRNA abundance quantification through 
deep sequencing analysis.  
The gRNA cassette MiSeq deep sequencing library was constructed using a similar 
method as previously described7. Genomic DNA was extracted using QiAamp DNA mini 
kit (Qiagen #51304), following the manufacturer’s protocol. In order to maintain 
approximately one thousand-fold gRNA library representation, 25 parallel PCR reactions 
were performed to amplify the gRNA cassette using the 2X High Fidelity Phusion Master 
Mix (Thermo Scientific #F-548). PCR products were subjected to Illumina MiSeq library 
construction and sequencing. First, the PCR product was end repaired with T4 DNA 
polymerase (New England BioLabs, NEB), DNA polymerase I (NEB), and T4 
polynucleotide kinase (NEB). Then, an A overhang was added to the end-repaired DNA 
using Klenow DNA Pol Exo- (NEB). The A-overhang DNA fragment was ligated with 
diversity-increased barcoded Illumina adaptors followed by seven pre-capture PCR cycles. 
The barcoded libraries were pooled at an equal molar ratio and subjected to massively 
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parallel sequencing through a MiSeq instrument (Illumina) using paired-end 150-bp 
sequencing (MiSeq Reagent Kit v2; Illumina MS-102-2002). 
The sequence data were de-barcoded and trimmed to contain only the gRNA sequence, 
and subsequently mapped to the reference gRNA library without allowing any mismatches. 
The read counts were calculated for each individual gRNA. To calculate the relative 
abundance of each gRNA, the read counts of each gRNA were divided by the total read 
counts of the pooled gRNA library.  
 
Validation of the Catalytic domain-specific screen 
RN2C cells or NIH3t3 mouse fibroblast cells were infected with LRG lentiviral vectors 
expressing GFP and a single gRNA targeting the catalytic domain of the indicated RNA 
enzymes and controls. The % of GFP+ cells was measured at day 2 after infection as a 
baseline by flow cytometry. The % of GFP+ cells was measured again at day 10 and day 
12 for RN2C or NIH3T3 cells, respectively. Three gRNAs from Screen 2 were used for 
each target and one gRNA for the rosa26 locus as a negative control. The gRNA 
sequences are listed in the supplementary material table. The data were analysed using 
Flowjo software. 
 
gRNA competition  
gRNA competition assays were performed using single and dual gRNA vectors as 
described previously2. For the validation of individual target genes, one gRNA was derived 
from the CRISPR library used in the screens and another gRNA was designed using WTSI 
Genome Editing website (http://www.sanger.ac.uk/htgt/wge/). Viral supernatants were 
collected 48 h after transfection. All transfections and viral collections were performed in 
24-well plates and transduction was performed as mentioned above. For gRNA/BFP 
competition assays, flow cytometry analysis was performed on 96-well plates using a 
LSRFortessa instrument (BD). Gating was performed on live cells using forward and side 
scatter, before measuring of BFP+ cells. The gRNA sequences are listed in the 
supplementary material table. 
Efficiency of genome editing in the pool of sgRNA-targeted cells was evaluated by 
Tracking of Indels by Decomposition (TIDE)32. 
 
Replating Assays 
For re-plating assays, 5,000 lineage negative cells and primary murine AML cells 
expressing Cas9 were plated in three wells of 6-well-plate of M3434 methylcellulose (Stem 
Cell Technologies) after infection with lentiviral vectors expressing gRNAs targeting the 
catalytic domain of METTL3 or empty vectors.  The colonies were counted 7 days later 
and further 5,000 cells re-seeded and re-counted after a week until no colonies were 
observed (for WT) or until the 3rd replating (for primary murine AMLs). 
 
Flow cytometry analyses of AML cells  
Cas9 expressing cells were transduced with gRNA vectors targeting the catalytic domain 
of METTL3 or empty vectors and stained with anti-mouse CD11b PE/Cy5 (Biolegend, cat. 
no. 101210) and anti-human CD11b PE (eBiosciences, cat. no. 9012-0118). Data were 
analysed by using LSRFortessa (BD) and FlowJo.  
 
Mouse whole-body bioluminescent imaging  
For in vivo experiments, MOLM13 cells expressing Cas9 were transduced with a firefly 
luciferase-expressing plasmid (System Biosciences). After propagation, the cells were 
transduced with a lentivirus either empty or expressing Mettl3 gRNA (day 0) and selected 
with puromycin from day 2 to day 5. At day 5 post transduction, the cells were suspended 
in fresh medium without puromycin. At day 6, 1 x 105 cells were transplanted into female 
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6-week old Rag2-/- IL2RG-/- mice by tail-vein injection. At day 14 post-transplant, the 
tumour burdens of the animals were detected using IVIS Lumina II (Caliper) with Living 
Image version 4.3.1 software (PerkinElmer). Briefly, 100 μl of 30 mg/ml D-luciferin 
(BioVision) was injected into the animals intraperitoneally. Ten min after injection, the 
animals were maintained in general anaesthesia by isoflurane and put into the IVIS 
chamber for imaging. The detected tumour burdens were measured and quantified by the 
same software.  Animals were culled when the tumour burden was 108 photons per 
second or higher. Diseased mice welfare was assessed blindly by qualified animal 
technicians from the Sanger mouse facility. All animal studies were carried out in 
accordance with the Animals (Scientific Procedures) Act 1986, UK and approved by the 
Ethics Committee at the Sanger Institute. Randomisation and blinding were not applied.  
 
Conditional Knock-Down cells generation. 
5*105 MOLM13 or THP1 cells were infected as described above using PLKO-TETon-Puro 
lentiviral vectors expressing shRNAs against the coding sequence of human METTL3, 
CEBPZ or a scramble control. 24 hours after spinfection the cells were replated in fresh 
medium containing 1 ug/ml of puromicin and kept in selection medium for 7 days. ShRNA 
was induced by 200 ng/ml doxycycline treatment for the indicated times. The shRNA 
sequences are listed in the supplementary material table.  
 
Proliferation assays 
5*104 MOLM13 or THP1 CTRL or METTL3 KD cells (4 days after doxycycline induction) 
were seeded in 2 ml of complete RPMI medium and counted 4 days after plating using the 
Countess II cell counter. For SP1 rescue experiments the number of doxycycline treated 
cells were normalised to their untreated counterparts.  
 
Rescue Experiments 
cDNA was obtained by reverse transcription of MOLM13 RNA with Supercript III 
(ThermoFisher Scientific), then SP1 full length coding sequence was amplified by PCR 
and cloned into pHIV-ZsGreen plasmid (Addgene #18121) by Gibson assembly (Gibson 
Assembly® Cloning Kit, NEB), using the HpaI site. 
MOLM13 cells were transduced with the lentiviral constructs, then GFP+ cells were 
isolated by flow cytometry sorting after 5 days and employed in proliferation assays as 
descripted in the previous section. 
For rescue experiments with either active or catalytically mutant METTL3, pcDNA3/Flag-
METTL3 plasmid (Addgene #53739) was mutagenized at the positions D394A (GAC / 
GCC) and W397A (TGG / GCG) as described by Fustin et al33 with QuikChange II Site-
Directed Mutagenesis Kit (Stratagene).  
NPM1cFlt3Itd/+/Rosa26Cas9/+ cells were transduced with an empty or domain-specific Mettl3 
gRNA lentiviral vector and selected with puromycin until day 5 post-transduction. Then 
cells were electroporated in Buffer R (Invitrogen) with the plasmids encoding WT METTL3, 
catalytically inactive METTL3 or an empty vector as a control. In each replicate 150,000 
cells were electroporated with 500 ng of each plasmid and plated in triplicate at 50,000 
cells per well in a 6-well plate. Electroporation was performed using the Neon Transfection 
System (Thermo Fisher Scientific) as previously described34. 3 days after electroporation 
(day 8), live cells were measured per well/condition. 
 
METTL3 overexpression/proliferation experiments 
AML cells were electroporated in Buffer R (Invitrogen) with plasmids encoding the WT 
METTL3 or an empty vector as a control. In each replicate 200,000 cells were 
electroporated with 500 ng of each plasmid and plated in triplicate at 50,000 cells per well 
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in a 6-well plate. 2 days after electroporation (day 3), live cells were measured per 
well/condition. 
 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation was performed as previously described35. Firstly MOLM13 
cells were cross-linked with 0.5% formaldehyde for 10 minutes.  20*106 cells were used for 
each immunoprecipitation with 3 μg of specific antibodies or IgG. Immunoprecipitated DNA 
was purified with ChIP DNA Clean & Concentrator Columns (Zymo) and either amplified 
for massive parallel sequencing or analysed on an ABI 7900 real-time PCR machine, Fast 
SybrGreen PCR mastermix according to the manufacturer’s instructions. Primer 
sequences are listed in the supplementary material table. 
 
ChIP-sequencing 
For the METTL3, METTL14, H3K4me3 and IgG ChIP-Seq experiment 5, 5, 2 and 3 
independent biological replicates were used, respectively. Single end 50bp libraries were 
prepared using the Bioo Scientific NEXTflex ChIP-Seq kit following manufacturer's 
recommendations. Reads were sequenced using HiSeq 1500 and multiplexed reads were 
split based on their barcodes using Illumina Basespace. Reads were trimmed to remove 
the TRUseq adapter using trim_galore 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore) with parameters '-q 0 -a 
AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC --phred33 --fastqc'. Read quality 
was assessed using FastQC. Ribosomal contamination was removed by first mapping the 
reads to hg38 rDNA sequences using bwa36 (default parameters), and removing all reads 
that mapped. Trimmed non-ribosomal reads were mapped to the hg38 genome using bwa 
with parameters '-n 3 -k 2 -R 300 -t 4'. Multiple reads mapping to a single genomic locus 
were treated as PCR duplicates, and were removed using samtools rmdup37. Mapped 
reads were filtered to remove reads mapping to more than one unique genomic locus 
(multihits) by keeping only reads with flag XT:A:U in the output bam file from bwa. Reads 
were further filtered to remove those with mapping quality less than 20 using samtools. 
Genome coverage bedgraph files were generated using genomeCoverageBed from the 
bedtools38 suite of tools. Coverage files were converted to bigwig format using 
bedGraphToBigWig. Peaks were called against input sample using MACS2 using default 
parameters39. Peaks from all replicates were merged to give a master list of potential 
binding loci per condition, and read count (normalised by overall read depth of the library) 
for each replicate was calculated using the GenomicRanges package in R40. Peaks were 
treated as potential binding loci if all replicates showed normalised score greater than 1 
and did not overlap a peak called in the IgG. Genomic annotation of ChIP peaks and reads 
and gene set operations were performed taking advantage of the R packages 
ChIPseeker41 and VennDiagram42, respectively. HOMER tool suite43 was used for DNA 
motif discovery coupled with the hypergeometric enrichment calculations (or binomial) to 
determine motif enrichment. 
 
 
m6A RNA IP-sequencing 
Total RNA was isolated from MOLM13 CTRL cells or METTL3KD cells (2 independent 
biological replicate for each shRNA) 8 days after doxycycline administration using the 
RNAeasy midi Kit (Quiagen). Successively polyA+ RNA was purified from 300μg of total 
RNA using the NEBNext® Poly(A) mRNA Magnetic Isolation Module (New England 
Biolabs). 500 ng of polyA+ purified RNA was used for each immunoprecipitation reaction. 
m6A RNA immunoprecipitation was performed using the Magna MeRIP™ m6A kit 
(Millipore) according with the manufacturer instructions. 
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Single end 50bp stranded libraries were prepared using the Bioo Scientific NEXTflex 
Rapid Directional RNA kit following manufacturer's recommendations. Reads were 
sequenced using HiSeq 4000 and multiplexed reads were split based on their barcodes 
using Illumina Basespace. Reads were trimmed to remove the TRUseq adapter using 
trim_galore with parameters: 
 '-q 0 -a AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC --phred33 --fastqc'.  
Read quality was assessed using FastQC. Ribosomal contamination was removed by first 
mapping the reads to hg38 rDNA sequences using bwa (default parameters), and 
removing all reads that mapped. Trimmed non-ribosomal reads were mapped to the hg38 
genome using Tophat2 with parameters '--no-coverage-search --max-multihits 300 --
report-secondary-alignments --read-mismatches 2'. Gene annotations from Ensembl v86 
were used to direct transcript alignment. Mapped reads were filtered to remove those 
mapping to more than one unique genomic locus (multihits) by keeping only reads with 
flag NH:i:1 in the output bam file from Tophat. Reads were further filtered to remove the 
ones with mapping quality less than 20 using samtools. Genome coverage bedgraph files 
were generated for forward and reverse strand reads using genomeCoverageBed from the 
bedtools suite of tools. Coverage files were converted to bigwig format using 
bedGraphToBigWig. Transcript assembly was performed using cufflinks2 and a single 
transcript database was generated using cuffmerge44. Statistical analysis of differentially 
methylated peaks in CTRL and METTL3 KD cells was performed using the R package 
MeTDiff45. Metagene plots were generated by RNAModR package 
(https://github.com/mevers/RNAModR), while m6A motifs were analysed according to 
published protocols46. For evaluating statistical significance of [GAG]n motif enrichment, 
individual motif occurrences were searched throughout human transcriptome with FIMO 
program (MEME suite47). 
 
Ribosome profiling 
Ribosome profiling was obtained using the Illumina TruSeq® Ribo Profiler (Mammalian) kit. 
5*107 MOLM13 CTRL (2 pooled independent biological replicates) or METTL3 KD cells (2 
pooled independent biological replicates for each shRNA) 5 or 8 days after doxycycline 
induction were treated with 0.1 mg/ml of cycloheximide for 1 minute and the RPF fraction 
of mRNA was isolated following the manufacturer instruction. Ribosomal RNA was 
removed using the Illumina Ribozero Kit. 
Single end 50 bp stranded libraries were prepared following manufacturer's 
recommendations. Reads were sequenced using HiSeq 1500 and multiplexed reads were 
split based on their barcodes using Illumina Basespace. Reads were trimmed to remove 
the TRUseq adapter using trim_galore with parameters '-q 0 -a 
AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC --phred33 --fastqc'. Read quality 
was assessed using FastQC. Ribosomal contamination was removed by first mapping the 
reads to hg38 rDNA sequences using bwa (default parameters), and removing all reads 
that mapped. Trimmed non-ribosomal reads were mapped to the hg38 genome using 
Tophat2 with parameters '--no-coverage-search --max-multihits 300 --report-secondary-
alignments --read-mismatches 2'. Gene annotations from Ensembl v86 were used to direct 
transcript alignment. Mapped reads were filtered to remove those mapping to more than 
one unique genomic locus (multihits) by keeping only reads with flag NH:i:1 in the output 
bam file from Tophat. Reads were further filtered to remove the ones with mapping quality 
less than 20 using samtools. Genome coverage bedgraph files were generated for forward 
and reverse strand reads using genomeCoverageBed from the bedtools suite of tools. 
Coverage files were converted to bigwig format using bedGraphToBigWig. Transcript 
assembly was performed using cufflinks and a single transcript database was generated 
using cuffmerge. Statistical analysis of differentially translated genes in CTRL and 
METTL3 KD cells was performed using the R package xtail48. In order to estimate the 
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offset value relative to the read start required to localize the position of P-sites (in our case 
~12nt, as already described in the literature), we employed the function “psite” of the 
plastid Python library49. 
 
Polysome fractionation 
5*107 MOLM13 CTRL (2 pooled independent biological replicates) or METTL3 KD cells (2 
pooled independent biological replicates) 8 days after doxycycline induction were treated 
with 0.1 mg/ml of cycloheximide for 5 minutes at 37°C, then they were lysed and 
polysomes were fractionated on a sucrose gradient as described before50. Relative RNA 
abundance in each fraction was then quantified by RT-qPCR. 
 
RNA-sequencing 
Input samples from the m6A RNA IP and Riboprofiling experiments were combined to give 
a set of transcriptional profiling samples to treat as an RNA seq experiment (CTRL n=4, 
METTL3 KD n=6). Gene counts were calculated at the transcript level for the combined 
transcript database from cuffmerge using summarizeOverlaps from the 
GenomicAlignments40 package in R using a generalized linear model fit which takes into 
account possible batch effects of the two distinct experiments. Differential gene expression 
analysis was conducted using DESeq2ref.51. Differentially expressed genes were identified 
as those with RPKM greater than 1 for WT or KD showing differential expression greater 
than 2 fold (up or down) with a Benjamini and Hochberg corrected p value less than 0.05 
unless stated otherwise. 
Gene set enrichment analysis was performed using R package GAGE52.  
 
Construction of the engineered translation reporter system 
A DNA sequence carrying 10 GAL4 recognition motifs (or a scrambled version of the same 
sequence) was in vitro synthetized and cloned into pMirGlo plasmid (Promega) upstream 
to the constitutive PGK promoter by cutting with BglII and ligating with T4 DNA ligase 
(NEB). The sequence of SP2 known to harbor the m6A peak and the [GAN]n motif was 
amplified by PCR and subcloned in frame at the N-terminus of Firefly luciferase by Gibson 
assembly (Gibson Assembly® Cloning Kit, NEB), using the ApaI site. 
To generate GAL4-METTL3(CD) construct, The CREB coding sequence in plasmid 
pcDNAI-GAL4-CREB-S133A (Addgene #46770) was swapped with METTL3 catalytic 
domain obtained by plasmid pcDNA3/Flag-METTL3 (Addgene #53739) using restriction 
enzymes XbaI and EcoRI. Wild type METTL3, was mutagenized at the positions D394A 
(GAC / GCC) and W397A (TGG / GCG) as described by Fustin et al33 with QuikChange II 
Site-Directed Mutagenesis Kit (Stratagene).  Cloning primer sequences are listed in the 
supplementary material table. 
 
Luciferase assay 
293T cells were co-transfected with the GAL4-METTL3 construct and UAS-SP2-Luc or 
SCR-SP2-Luc vectors expressing the Renilla luciferase as transfection control. 24 hours 
after transfection the Firefly and Renilla lucipherases activities were measured using the 
Dual-Luciferase Reporter Assay System (Promega) on CLARIOstar microplate reader 
(BMG Labtech). 
Alternatively, transfected cells were lysed and total RNA extracted using the Qiagen 
RNAeasy Mini kit according to the manufacturer instructions. 
 
Western blotting 
Western blotting was performed as previously described53. For the isolation of nuclei from 
the cytoplasmic fraction, cells were incubated in hypotonic buffer (20mM Tris-HCl, pH 7.4, 
10mM NaCl, 3mM MgCl2,) and the cytoplasmic membranes disrupted by adding 0.5% 
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NP40. Pelleted nuclei were successively lysed in IPH buffer (50mM Tris-HCl pH=8.0, 
150mM NaCl, 5mM EDTA, 0.5% NP-40) for 10 minutes on ice. Nucleoplasmic and 
chromatin fractions were separated by 15 minutes centrifugation at 4°C. The chromatin 
fraction was resuspended and sonicated in Laemmli buffer before loading on SDS-PAGE. 
 
RT-qPCR  
Total RNA from MOLM13, THP1 or 293T cells was purified using the RNAeasy mini kit 
according to the manufacturer instructions. 1μg of purified total RNA was retrotranscribed 
using the High capacity cDNA reverse transcription kit  (Applied Biosystems). The levels of 
specific RNAs were measured using the ABI 7900 real-time PCR machine and the Fast 
SybrGreen PCR mastermix according to the manufacturer’s instructions. Firefly luciferase 
levels were normalised on Renilla luciferase levels while METTL3 mRNA levels were 
normalised on β-ACTIN mRNA. For quantification of polysome fractionation and m6A-RIP 
experiments, probes from Universal ProbeLibrary (Roche) were used with TaqMan® Fast 
Advanced Master Mix (ThermoFisher). Primer sequences are listed in the Supplementary 
Material tables. 
 
Antibodies 
For the ChIP experiments the following antibodies were used: anti-METTL3 from Bethyl 
Laboratories (A301-568A), anti-METTL3 from Bethyl Laboratories (A301-567A), rabbit 
polyclonal anti-METTL14 from Abcam (ab98166), anti H3k4me3 from Abcam (ab8580) 
and IgG  Isotype Control (ab171870). 
Western blot experiment were performed using the following antibodies: anti-METTL3 from 
Bethyl Laboratories (A301-568A), anti-METTL14 from Abcam (ab98166), anti-Histone H3 
from Active motif (39763), anti-WDR5 from Abcam (ab178410), anti-CEBPZ from Abcam 
(ab176579), anti-SP1 from Abcam (ab13370) and anti-SP2 from Abcam (ab137238), anti-
ACTIN from Abcam (ab8227). 
 
Statistical analysis 
All general statistical analyses were performed using either a two-tailed Student’s t-test or 
a Wilcoxon test (when distributions were assessed not to be normal and homoscedastic) 
at a confidence interval of 95%, unless differently specified. 
 
Availability of data and material 
Raw sequencing data have been deposited in the Gene Expression Omnibus database 
with accession code: GSE94613 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= 
GSE94613). 
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Extended Data Figure Legends 498 
 499 
 500 
 501 
Extended Data Figure 1 (Related to Figure 1) 502 
Validation of CRISPR screens. 503 
a) Correlation between gene rankings from the two independent CRISPR-Cas9 screens. 504 
Goodness of fit is calculated as Pearson Correlation Coefficient. b) Average ratio of the 505 
percentage of GFP positive RN2C cells between day 2 and day 10 after infection with 506 
lentiviral vectors expressing GFP and individual gRNAs against the indicated targets. The 507 
mean +S.E.M. depletion of 3 different gRNAs against the catalytic domain of the targets is 508 
shown. gRNA targeting the Rosa26 locus was a negative control. Rpa (replication protein 509 
A) is a positive control. c) Competitive co-culture assay showing negative selection of 510 
BFP+ MOLM13 or MLL-AF9 primary mouse cells upon targeting of METTL3 by CRISPR-511 
Cas9. Cells were transduced with lentiviruses expressing four different gRNAs targeting 512 
the 5’ exons or the catalytic domain of METTL3 and the BFP-positive fraction was 513 
compared with the non-transduced population. Results were normalized to those at day 4 514 
for each gRNA. The mean ±S.D. of two independent infections is shown. d) Colony 515 
forming assay of MLL-ENL/FLT3-ITD Cas9-expressing cells targeting METTL3 (catalytic 516 
domain-specific) or CTRL showing decreased replating ability. CFU: colony forming units 517 
(***p< 0.001; t-test). The mean +S.D. of three independent experiments is shown. e) 518 
Average ratio of the percentage of GFP positive NIH-3T3 mouse fibroblasts between day 2 519 
and day 12 after infection with lentiviral vectors expressing GFP and individual gRNAs 520 
against the indicated targets. The mean ±S.E.M. depletion of 3 different gRNAs against 521 
the catalytic domain of the targets is shown. Rpa (replication protein A) is a positive control. 522 
f) Colony forming assay of lineage negative haematopoietic Cas9-expressing cells 523 
targeting METTL3 (catalytic domain-specific; right panel) or CTRL. CFU: colony forming 524 
units (***p< 0.001; t-test). The mean +S.D. of three independent experiments is shown. g) 525 
Competitive co-culture assay showing negative selection of BFP+ AML cell lines upon 526 
targeting of METTL3, METTL1, METTL14 and METTL16 by CRISPR-Cas9 using two 527 
independent gRNAs for each target. Cells were transduced with lentiviruses expressing 528 
BFP and four different gRNAs targeting the 5’ exons or the catalytic domain of each target 529 
and the BFP-positive fraction was compared with the non-transduced population. Results 530 
were normalized to those at day 4 for each gRNA. The mean +S.D. of two independent 531 
infections is shown. 532 
 533 
Extended Data Figure 2 (Related to Figure 1) 534 
Effects of targeting METTL factors In human cancer cell lines. 535 
a) Competitive co-culture assay showing negative selection of BFP+ human cancer cell 536 
lines upon targeting of METTL3, METTL1, METTL14 and METTL16 by CRISPR-Cas9 537 
using two independent gRNAs for each target. The experiment was performed as 538 
described above. b) Efficiency of genome editing for gRNAs targeting METTL3, METTL1, 539 
METTL14 and METTL14 was measured across the indicated 20 human cell lines through 540 
TIDE analysis. Efficiency of targeting was also measured in mouse primary cell lines for 541 
gRNAs targeting Mettl3. c) CD11b expression in METTL3 (catalytic domain-specific) 542 
targeted cells (THP1 human cell line) was measured by flow cytometry 6 days after 543 
infection. d) Haematoxylin eosin staining of human and mouse AML cell lines infected with 544 
a control gRNA or gRNAs targeting the catalytic domain of METTL3. e) Time course 545 
quantification of luminescence from mice transplanted with luciferase-labelled MOLM13 546 
cells targeting METTL3 using gRNAs specific for the catalytic domain or CTRL (***p < 547 
0.001). 548 
 549 
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Extended Data Figure 3 (Related to Figure 1) 550 
METTL3 depletion in AML human cell lines leads to cell cycle arrest. 551 
a) METTL3 mRNA levels detected by RT-qPCR 4 days after shRNAs induction with 552 
doxycycline in MOLM13 cells. The mean ±S.E.M. of four independent cultures is shown. b) 553 
Western blot showing METTL3 and H3 levels in MOLM13 cells infected with specific or 554 
CTRL TET-inducible shRNAs 5 days after doxycycline treatment. For gel source data see 555 
Supplementary Information. c) METTL3 mRNA levels detected by RT-qPCR 4 days after 556 
shRNA induction with doxycyxline in THP1 cells (left panel). The mean ±S.E.M. of three 557 
independent cultures is shown. A proliferation assay of the cells was then performed with 558 
cell numbers measured between day 0 (4d post doxycycline) and day 4 (8d post 559 
doxycycline) (right panel). The mean ±S.D. of two independent replicates is shown. d) 560 
Western blot for METTL3 and actin in mouse AML cells. MPN1c/Flt3ltd/+/Rosa26Cas9/+ 561 
mouse AML cells were transduced with gRNAs targeting the catalytic domain of Mettl3 and 562 
plasmids expressing either wild type METTL3 or a catalytically inactive mutant (DW/AA). 563 
For gel source data see Supplementary Information. e) Volcano plots for CTRL vs 564 
METTL3 KD samples, showing the significance p-value (log10) versus. Fold Change (log2) 565 
of gene expression. Significantly upregulated and downregulated transcripts are shown in 566 
red (|logFC|>1, p<0.001, FDR<0.01). f) Graphical representation of KEGG pathways 567 
regulation showing cell cycle down-regulation (upper panel) and haematopoietic 568 
differentiation up-regulation (lower panel) as obtained by comparing RNA-seq derived from 569 
METTL3 KD and CTRL MOLM13 cells (up-regulated genes: red; down-regulated genes: 570 
green). 571 
 572 
Extended Data Figure 4 (Related to Figure 1 and 2) 573 
METTL3 is overesxpressed in human AML and it is recruited on chromatin. 574 
a) METTL3 (top panel) and METTL14 (lower panel) mRNA expression levels across 575 
cancer types from the TCGA database. b) Proliferation assay of human AML cell lines 576 
upon transduction with a vector expressing METTL3. Cell numbers were measured 577 
between day 1 and day 3 after electroporation. The mean +S.D. of three independent 578 
replicates is shown. c) Western blot for METTL3 and METTL14, GAPDH and histone H3 579 
on cytoplasmic, nucleoplasmic and chromatin fractions from MOLM13 cells. For gel source 580 
data see Supplementary Information. d) Genomic browser screenshot of METTL14 and 581 
H3K4me3 normalised ChIP-seq datasets on the human SP2 gene locus from MOLM13 582 
cells. e) Pie charts of genomic regions associated with METTL14 (top) and METTL3 583 
(bottom) ChIP-seq peaks. f) Distribution of METTL14 ChIP-seq reads centred on TSSs 584 
(upper panel) and histogram of ChIP-seq reads distribution relative to TSSs (lower panel). 585 
g) Top: Venn diagram showing the overlap between METTL3 and METTL14 peak 586 
datasets (statistical significance was evaluated by a χ2-test). Bottom: Distribution of 587 
METTL3 and METTL14 ChIP-seq reads centred on METTL14 (left panel) or METTL3 588 
(right panel) peaks. 589 
 590 
Extended Data Figure 5 (Related to Figure 2) 591 
Validation of METTL3 ChIP-seq. 592 
a) ChIP-seq validation by ChIP-qPCR of METTL3 and METTL14 binding on the SP2 and 593 
RFX1 loci. The mean of six technical replicates ±S.D. is shown. The experiment was 594 
performed independently three times. b) METTL3 ChIP-seq validation by ChIP-qPCR on 595 
the indicated loci. The LMO2 promoter was used as a negative control. The mean of three 596 
technical replicates ±S.D. is shown. The experiment was performed independently three 597 
times. c) METTL3 ChIP-seq validation by ChIP-qPCR on the indicated TSSs using two 598 
independent METTL3 antibodies in MOLM13 cells. The mean of six technical replicates 599 
±S.D. is shown. The experiment was performed independently three times. d) METTL3 600 
ChIP-seq validation by ChIP-qPCR on the indicated TSS in CTRL or METTL3 KD 601 
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MOLM13 cells, showing a specific reduction of METTL3 binding in KD cells. The mean of 602 
three technical replicates ±S.D. is shown. The experiment was performed independently 603 
three times.  604 
 605 
Extended Data Figure 6 (Related to Figure 2) 606 
METTL3 colocalise with a defined set of chromatin factors. 607 
a) Motif discovery analysis of the genomic sequences under METTL3 ChIP-seq peaks 608 
using HOMER. Significance was obtained using a hypergeometric test. b) Distribution of 609 
ChIP-seq reads for the indicated factors or histone modifications, centred on METTL3 610 
(green) and METTL14 (blue) ChIP peaks. Statistical significance of the binary overlap was 611 
evaluated by a χ2-test. c) Venn diagram showing the overlap of H3R2me2s, WDR5, KLF9, 612 
NFYA and NFYB ChIP-seq peaks after filtering for H3K4me3 promoters. d) Venn diagram 613 
showing significant overlap between METTL3 but not METTL14 peaks with the 447 loci 614 
carrying all five factors as in panel above. Statistical significance of the binary overlap was 615 
evaluated by a χ2-test.  616 
 617 
Extended Data Figure 7 (Related to Figure 2) 618 
CEBPZ recruits METTL3 on chromatin. 619 
a) Histogram representing the positive predictive power of the combined 5 factors 620 
compared with the predictive power of the ENCODE factors whose expression levels are 621 
tightly correlated with METTL3 expression. b) Correlation between CEBPZ and METTL3 622 
mRNA expression levels in the Human Protein Atlas RNA-seq datasets, including non-623 
transformed (blue) and cancer (pink) cell lines. (ρ= Spearmann correlation coefficient). c) 624 
Genomic plot of METTL3 and CEBPZ normalised ChIP-seq datasets on the human SP1 625 
and SP2 gene loci in MOLM13 and K562 cells, respectively. d) Distribution and heatmaps 626 
of normalised ChIP-seq reads for METTL3 centred on CEBPZ peaks. e) Distribution and 627 
heatmaps of normalised ChIP-seq reads of METTL14 and CEBPZ centred on METTL14 628 
(left panel) and CEBPZ (right panel) peaks. f) Competitive co-culture assay showing 629 
negative selection of BFP+ AML cell lines upon targeting of CEBPZ by CRISPR-Cas9 630 
gRNAs. Cells were transduced with lentiviruses expressing a gRNA targeting the first exon 631 
of CEBPZ and the BFP-positive fraction was compared with the non-transduced 632 
population. Results were normalized to those at day 4. The mean +S.D. of two 633 
independent infections is shown. g) CEBPZ mRNA levels detected by RT-qPCR 4 days 634 
after shRNA induction with doxycycline in MOLM13 cells. The mean ±S.D. of three 635 
independent cultures is shown. 636 
h) A proliferation assay of the CEBPZ CTRL and KD cells was performed with cell 637 
numbers measured between day 0 (4d post doxycycline) and day 4 (8d post doxycycline). 638 
The mean ±S.D. of six independent replicates is shown. i) ChIP-qPCR of METTL3 binding 639 
on target TSSs in and MOLM13 cells, expressing a control shRNA or two independent 640 
shRNAs against CEBPZ, showing a specific reduction of METTL3 binding in CEBPZ KD 641 
cells. The mean of three technical replicates +S.D. is shown. The experiment was 642 
performed independently three times. j) Box plot representing the expression levels of 643 
METTL3 targets upon METTL3 KD from the dataset shown in Extended Data Figure 3e. 644 
 645 
Extended Data Figure 8 (Related to Figure 3) 646 
Validation of the m6A RNA-IP upon METTL3 depletion.  647 
a) Motif analysis under the identified m6A-IP peaks showing enrichment of the expected 648 
UGCAG and GGACU sequences and their central distribution throughout the m6A-IP 649 
peaks, as obtained by MEME and CentriMo. b) Distribution of m6A-IP reads throughout 650 
the mRNA metatranscript, showing the expected enrichment around the STOP codon in 651 
MOML13 cells. c) Scatter plots and density plot showing the general down-regulation of 652 
m6A-IP signal upon METTL3 knock-down in MOLM13 cells. d) Histogram showing 653 
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METTL3–dependent m6A-IP read coverage in mRNAs from METTL3-bound TSSs (ChIP), 654 
whole transcriptome (All) or the permutation of random sets of genes (Rand). e) m6A-IP 655 
followed by qPCR for m6A peaks of HNRNPL or GAPDH as a control. The plot show the 656 
m6A-IP signal over total input in MOLM 13 cells expressing a control shRNA or shRNAs 657 
targeting CEBPZ. Mean ±S.D. of three technical replicates are shown; the experiment has 658 
been performed independently twice. f) SP1, SP2, HNRNPL and METTL3 mRNA levels 659 
detected by RT-qPCR 8 days after doxycycline induction in MOLM13 CTRL or CEBPZ KD 660 
cells. The mean ±S.D. of three independent cultures is shown. g) Histogram showing the 661 
enrichment of the [GAG]n motif within the transcript sequences of METTL3 ChIP-targets 662 
compared with random permutations of genes. 663 
 664 
Extended Data Figure 9 (Related to Figure 3) 665 
Ribosome profiling analysis. 666 
a) Distribution of ribosome profiling reads throughout the mRNA metatranscript from RNA 667 
inputs or ribosome-protected fragments (RPF) showing absence of 3’UTR specifically in 668 
the RPF dataset. b) Reading frame analysis of ribosome profiling reads from RNA inputs 669 
and RPF in MOLM13 cells showing enrichment of the 0 reading frame specifically in the 670 
RPF reads. c) Average read alignments to 5' and 3' ends of coding sequences in RNA 671 
inputs (upper panel) or RPF (lower panel) showing triplet periodicity and accumulation of 672 
reads on the start site typical of cycloheximide pre-treatment. d) Principal component 673 
analysis of P-site codon distribution on mRNAs from METTL3-bound TSSs as obtained by 674 
ribosome footprinting, 5 or 8 days after doxycycline administration, of METTL3 KD (KD5, 675 
KD8) or CTRL (WT5, WT8) MOLM 13 cells. e) Principal component analysis of P-site 676 
codon distribution on all mRNAs, as above. f) Frequency of P-site occupancy of codons in 677 
METTL3 KD or CTRL MOLM13 cells for either all coding genes or genes harbouring a 678 
METTL3 ChIP peak on their promoter (*p<0.05; t-test). g) Frequency of codons within the 679 
coding sequence of METTL3 chromatin targets compared with the general frequency 680 
throughout the coding transcripts. The plot shows no significant overrepresentation of GAN 681 
codons in the METTL3 chromatin targets. 682 
 683 
Extended Data Figure 10 (Related to Figure 4) 684 
METTL3 controls the translation of SP1 and SP2. 685 
a) RNA-seq normalised counts of SP1 and SP2 mRNAs from CTRL or METTL3 KD 686 
MOLM13 cells at day 8 after doxycycline induction. Mean +S.D. of at least three biological 687 
replicates are shown; b) Western blot showing CEBPZ, SP1 and GAPDH levels in CTRL 688 
and CEBPZ KD cells. For gel source data see Supplementary Information. c) Polysome 689 
fractionation analysis. Cell extracts from CTRL or METTL3 KD cells were prepared and 690 
resolved in 5 to 50 % sucrose gradient. The absorbance at 254 was continuously 691 
measured. The peaks corresponding to free 40S and 60S subunits, 80S and polysomes 692 
are indicated. d) DICER1 and ACTIN mRNAs in each ribosome fraction were quantified 693 
through qPCR and plotted as a percentage of the total. Data are from two independent 694 
polysome-profiling experiments. Mean ±S.E.M. are shown. e) Firefly luciferase activity in 695 
FADU cell line from UAS or scrambled (SCR) sequence carrying plasmid in presence of 696 
GAL4 either alone or fused with METTL3 wild type (CD) or inactive (CD DW/AA) catalytic 697 
domain (*p<0.05; t-test). The mean +S.D. of three independent transfections is shown. f) 698 
Firefly luciferase mRNA from plasmids carrying UAS or scrambled sequence in presence 699 
of GAL4 either alone or fused with METTL3 wild type (CD) or inactive (CD DW/AA) 700 
catalytic domain, as evaluated by qPCR. The mean ±S.D. of three replicates is shown. g) 701 
Box plot showing transcriptional modulation of genes bound by SP1, SP2 or both between 702 
METTL3 KD and CTRL MOLM13 cells (*p<0.05; Wilcoxon test). h) Genomic browser 703 
screenshot of SP1 and SP2 normalised ChIP-seq dataset on the human c-MYC gene 704 
locus in K562 cells (from ENCODE). i) Western blot showing METTL3, SP1 and ACTIN 705 
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protein levels in MOLM13 cells infected with METTL3-specific or CTRL TET-inducible 706 
shRNAs and with an SP1 expression vector 5 days after doxycycline treatment. For gel 707 
source data see Supplementary Information. 708 
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